Recent Updates in The Role of Immunotherapies in NSCLC: Translating Evidence to Clinical Practice - Episode 11

EMPOWER LUNG-3 Study of Chemoimmunotherapy in Advanced NSCLC

November 2, 2022

Solange Peters, MD, PhD, Melissa Johnson, MD, Myung-Ju Ahn, MD, Vamsidhar Velcheti, MD

Key opinion leaders discuss data from the EMPOWER-Lung-3 study investigating the use of cemiplimab plus chemotherapy in both squamous and non-squamous NSCLC.

EP. 1: Treatment Options for Early-Stage Non-Small Cell Lung Cancer (NSCLC)

EP. 2: The Role of Neoadjuvant Immunotherapy in the Treatment of Resectable NSCLC

EP. 3: Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials

EP. 4: Optimizing the Role of Neoadjuvant Immunotherapy in Resectable NSCLC

EP. 5: Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The NEOCoast Trial

EP. 6: The Role of Adjuvant Immunotherapy in the Treatment of Resectable NSCLC

EP. 7: Multidisciplinary Therapy and Molecular Testing in Early-Stage NSCLC

EP. 8: Updates in The Treatment of Advanced NSCLC with Immune Checkpoint Inhibitors

EP. 9: CheckMate-227 Study of Frontline Nivolumab and Ipilimumab in Advanced NSCLC

EP. 10: KEYNOTE-407 Study of Frontline Pembrolizumab and Chemotherapy in Advanced NSCLC

Now Viewing

EP. 11: EMPOWER LUNG-3 Study of Chemoimmunotherapy in Advanced NSCLC

EP. 12: POSEIDON Study of Dual Immunotherapy Regimens in Advanced NSCLC

EP. 13: Treatment Options in Patients with Advanced NSCLC Who Progress on Immunotherapy

EP. 14: The Role of Anti-TGIT Immunotherapies in the Treatment of Advanced NSCLC

EP. 15: The ARC-7 Trial of Anti-TGIT Immunotherapies in Advanced NSCLC

EP. 16: A Role for Immunotherapy in Patients with Concomitant KRAS and KEAP1/STK11/p53 Mutations

EP. 17: The Exciting Future of NSCLC Treatment

EP. 18: Is There a Role for IO Therapy in NSCLC With Independent KRAS, STK11, or KEAP1 Mutations?

EP. 19: POSEIDON Study Post-hoc Analysis: Outcomes in Patients With KRAS/STK11/KEAP1 Mutations

EP. 20: Selecting Optimal Treatment for NSCLC With KRAS/STK11, or KRAS/KEAP1 Mutations

EP. 21: Emerging Strategies for the Management of NSCLC With KRAS/STK11/KEAP1 Mutations

EP. 22: Treatment Strategies for NSCLC With Concomitant KRAS and p53 Mutations